| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/25/2011 | EP2325210A1 Monoclonal antibodies against Claudin-18 for treatment of cancer |
| 05/25/2011 | EP2325209A2 Improved protofibril selective antibodies and the use thereof |
| 05/25/2011 | EP2325205A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2325196A1 Replikin peptides and uses thereof |
| 05/25/2011 | EP2324855A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 05/25/2011 | EP2324852A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 05/25/2011 | EP2324851A1 Methods of administering anti-TNFalpha antibodies |
| 05/25/2011 | EP2324850A1 Solid vaccine formulation |
| 05/25/2011 | EP2324849A2 Selective immune down regulation (SIDR) mediated transplantation processes |
| 05/25/2011 | EP2324848A2 Method for treating intraocular neovascular diseases |
| 05/25/2011 | EP2324844A2 April receptor (BCMA) and uses thereof |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324839A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/25/2011 | EP2324113A1 Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| 05/25/2011 | EP2324112A1 Mutant pestivirus with mutations in core gene and ns3 region |
| 05/25/2011 | EP2324062A1 Chimeric respiratory syncytial virus polypeptide antigens |
| 05/25/2011 | EP2324061A1 Multispecific antibodies |
| 05/25/2011 | EP2324059A1 Anti-pamp therapeutic antibodies |
| 05/25/2011 | EP2324057A1 Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers |
| 05/25/2011 | EP2324053A2 Ferritin 2 for the host immunization against ticks |
| 05/25/2011 | EP2324051A1 Non-typhoidal salmonella vaccines |
| 05/25/2011 | EP2324050A1 Vaccine compositions |
| 05/25/2011 | EP2324049A2 Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine |
| 05/25/2011 | EP2323738A2 Use of a soluble form of hla-g in the treatment of abnormal b-lymphocyte proliferation |
| 05/25/2011 | EP2323691A2 Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
| 05/25/2011 | EP2323690A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
| 05/25/2011 | EP2323689A1 Treatment and/or prevention of peanut induced anaphylaxis |
| 05/25/2011 | EP2323684A2 Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen |
| 05/25/2011 | EP2323680A2 Proteins for use in diagnosing and treating infection and disease |
| 05/25/2011 | EP2323648A2 Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre |
| 05/25/2011 | EP2323628A2 Carrier nanoparticles and related compositions, methods and systems |
| 05/25/2011 | EP2323624A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 05/25/2011 | EP2082750B1 Oral recombinant helicobacter pylori vaccine and preparing method thereof |
| 05/25/2011 | EP1804834B1 Immunogenic bacterial vesicles with outer membrane proteins |
| 05/25/2011 | EP1664118B1 Tlr2 antagonistic antibody and use thereof |
| 05/25/2011 | EP1425035B1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 05/25/2011 | EP1381384B1 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| 05/25/2011 | EP1374902B1 Anti-AILIM antibodies for the treatment of Crohn's disease |
| 05/25/2011 | EP1263463B1 Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| 05/25/2011 | CN1887296B Method of inducing antitumor immunity and its application in preparing medicine |
| 05/25/2011 | CN1882698B Hypoxia-inducible protein 2 (HIG2)serving as a novel therapeutic potential target of renal cell carcinoma (RCC) |
| 05/25/2011 | CN1416352B Outer membrane vesicle (OMV) vaccine comprising N. Meningitidis serogroup B outer membrane |
| 05/25/2011 | CN1285752B Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 05/25/2011 | CN102076843A Compositions comprising prfa*mutant listeria and methods of use thereof |
| 05/25/2011 | CN102076716A Stable and soluble antibodies inhibiting tnfa |
| 05/25/2011 | CN102076361A Probiotics, secretory IgA and infection |
| 05/25/2011 | CN102076360A Probiotics, secretory IgA and inflammation |
| 05/25/2011 | CN102076359A Vaccine compositions and methods |
| 05/25/2011 | CN102076358A Novel adjuvant compositions |
| 05/25/2011 | CN102076357A Microneedle device, and method for enhancing efficacy of influenza vaccine by using microneedle devive |
| 05/25/2011 | CN102076356A Attenuated pestivirus |
| 05/25/2011 | CN102076355A Dual varistructure domain immunoglobulins and uses thereof |
| 05/25/2011 | CN102076354A Composition and methods for eliciting an immune response |
| 05/25/2011 | CN102071206A Adeno-associated virus capsid protein gene, corresponding protein and application of protein |
| 05/25/2011 | CN102071205A Specific antigen of clonorchis sinensis and application thereof |
| 05/25/2011 | CN102070715A Human antibodies that bind human TNF alpha |
| 05/25/2011 | CN102070710A Specific GRA2a (Glycine Rich Antigen)-type antigenic protein of clonorchis sinensis and application thereof |
| 05/25/2011 | CN102068698A Nanometer vaccine and preparation method thereof |
| 05/25/2011 | CN102068696A Freeze-dried powder injection with recombinant human tumor necrosis factor receptor (TNFR)-Fc fusion protein |
| 05/25/2011 | CN102068695A Method for producing quadruple inactivated vaccine for newcastle disease, infectious bronchitis, avian influenza (H9 subtype) and infectious bursal disease |
| 05/25/2011 | CN102068694A Method for producing triple inactivated vaccine for newcastle disease, infectious bronchitis and infectious bursal disease |
| 05/25/2011 | CN102068693A Application of complete Freund adjuvant (CFA) to preparation of tibia inflammatory pain model |
| 05/25/2011 | CN102068692A Influenza virus splitting vaccine and preparation method thereof |
| 05/25/2011 | CN102068691A Method for preparing high purity hand-foot-and-mouth disease vaccine with sucrose zonal ultracentrifugation |
| 05/25/2011 | CN102068690A Polyvalent pneumococcal capsular polysaccharide conjugate vaccine and preparation method thereof |
| 05/25/2011 | CN101670114B Compound of survivin and heat shock protein, preparation method and applications thereof |
| 05/25/2011 | CN101643721B Broad-spectrum safe anti influenza A virus vaccine for animals |
| 05/25/2011 | CN101492719B Uses of CXorf41 gene |
| 05/25/2011 | CN101417128B Preparation of BCG vaccine polysaccharide nucleic acid -DDA adjuvant and use thereof |
| 05/25/2011 | CN101361972B Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| 05/25/2011 | CN101151061B Coated microprojections having reduced variability and method for producing same |
| 05/25/2011 | CN101120015B Interleukin-15 antagonist peptide |
| 05/25/2011 | CN101085349B Vesicle guiding immunocyte and application of the same in preparing antineoplastic medicine |
| 05/25/2011 | CN101007169B A microcapsule of egg yolk immunoglobulin, preparing process and use thereof |
| 05/24/2011 | US7947822 HIV vaccines based on Env of multiple clades of HIV |
| 05/24/2011 | US7947812 Neoplasm specific antibodies and uses thereof |
| 05/24/2011 | US7947811 Antibodies that bind specifically to human RON protein |
| 05/24/2011 | US7947810 Kits for diagnosing a hypophosphatemic disorder |
| 05/24/2011 | US7947653 Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers |
| 05/24/2011 | US7947648 Methods for treating asthma in human and non human primates using IL-4 mutant compositions |
| 05/24/2011 | US7947496 Screening for cytotoxic end-points; cancerous disease modifying antibodies |
| 05/24/2011 | US7947480 Everninomicin biosynthetic genes |
| 05/24/2011 | US7947463 Diagnosing cancer; measure antibody inhibitor, compare to control, reduced amounts of inhibitor indicates receptivity to cancer |
| 05/24/2011 | US7947462 Methods for identifying Kremen polypeptide binding partners |
| 05/24/2011 | US7947460 Diagnosing/prognosing nut allergies; immunodiagnostics |
| 05/24/2011 | US7947459 Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 05/24/2011 | US7947452 Oligonucleotides originating from sequences coding for the surface component of PTLV envelope proteins and their uses |
| 05/24/2011 | US7947309 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
| 05/24/2011 | US7947304 Human growth hormone patch formulations |
| 05/24/2011 | US7947291 Modified surface antigen |
| 05/24/2011 | US7947290 Protease-resistant modified SEB and vaccine containing the same |
| 05/24/2011 | US7947289 Multimeric protein toxins to target cells having multiple identifying characteristics |
| 05/24/2011 | US7947287 Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors |
| 05/24/2011 | US7947286 Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain |
| 05/24/2011 | US7947282 Methods of treatment using vascular occlusion in combination therapies |
| 05/24/2011 | US7947281 Chimeric proteins that induce effects directed against viruses |
| 05/24/2011 | US7947280 G-protein coupled receptors; cardiovascular disorders; atherosclerosis, restenosis, ischemia, cardiomyopathy |
| 05/24/2011 | US7947279 Peptide having hydrolase activity |
| 05/24/2011 | US7947278 administer effective dose of human Egfl7 polypeptide agonist; intravenous, intra-arterial, intra-pericardial, systemic, subcutaneous, intramuscular, by inhalation, topical, transdermal; tumor growth, atherosclerosis, diabetic retinopathy, age-related maculopathy, and retrolental fibroplasia |